Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $135,420 | 60 | 88.7% |
| Travel and Lodging | $9,643 | 70 | 6.3% |
| Food and Beverage | $5,193 | 127 | 3.4% |
| Consulting Fee | $2,275 | 6 | 1.5% |
| Education | $107.49 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $55,928 | 89 | $0 (2019) |
| PFIZER INC. | $40,189 | 58 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $22,779 | 23 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $15,213 | 25 | $0 (2018) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $8,194 | 20 | $0 (2021) |
| Bayer HealthCare Pharmaceuticals Inc. | $6,313 | 6 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $2,741 | 8 | $0 (2017) |
| United Therapeutics Corporation | $331.89 | 11 | $0 (2024) |
| Genentech USA, Inc. | $214.18 | 2 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $168.49 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88.60 | 1 | United Therapeutics Corporation ($88.60) |
| 2022 | $277.25 | 7 | United Therapeutics Corporation ($116.60) |
| 2021 | $198.00 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($120.50) |
| 2020 | $11.37 | 1 | Smith+Nephew, Inc. ($11.37) |
| 2019 | $12,682 | 19 | Gilead Sciences, Inc. ($11,632) |
| 2018 | $48,295 | 77 | Gilead Sciences, Inc. ($27,770) |
| 2017 | $91,087 | 160 | PFIZER INC. ($30,019) |
All Payment Transactions
267 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/28/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $88.60 | General |
| 10/14/2022 | United Therapeutics Corporation | ORENITRAM (Drug) | Education | In-kind items and services | $2.50 | General |
| Category: PAH | ||||||
| 10/14/2022 | United Therapeutics Corporation | REMODULIN (Drug) | Education | In-kind items and services | $2.50 | General |
| Category: PAH | ||||||
| 10/14/2022 | United Therapeutics Corporation | REMODULIN (Drug) | Education | In-kind items and services | $2.50 | General |
| Category: PAH | ||||||
| 08/15/2022 | United Therapeutics Corporation | TYVASO (Drug), REMODULIN | Food and Beverage | In-kind items and services | $9.07 | General |
| Category: PAH | ||||||
| 08/12/2022 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $99.99 | General |
| Category: Cardiology | ||||||
| 06/13/2022 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $100.03 | General |
| 06/01/2022 | Sobi, Inc | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $60.66 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/14/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $120.50 | General |
| Category: RESPIRATORY | ||||||
| 08/17/2021 | Dova Pharmaceuticals | Doptelet (Drug) | Food and Beverage | In-kind items and services | $77.50 | General |
| Category: Hematology/Oncology | ||||||
| 12/21/2020 | Smith+Nephew, Inc. | GRAFIX PL (Biological) | Food and Beverage | In-kind items and services | $11.37 | General |
| Category: Other Advanced Wound Management | ||||||
| 11/18/2019 | Bayer HealthCare Pharmaceuticals Inc. | Adempas (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Cardio-pulmonary | ||||||
| 06/19/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $38.09 | General |
| 06/19/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $33.22 | General |
| 06/19/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.98 | General |
| 06/17/2019 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| 06/14/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $799.92 | General |
| 06/14/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $337.95 | General |
| 06/14/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $261.70 | General |
| 06/14/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.75 | General |
| 03/12/2019 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| 03/12/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $16.24 | General |
| 03/09/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $42.12 | General |
| 02/14/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $62.76 | General |
| 02/14/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $39.60 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 170 | 310 | $97,204 | $28,008 |
| 2022 | 5 | 157 | 310 | $120,728 | $33,031 |
| 2021 | 5 | 168 | 348 | $152,482 | $43,791 |
| 2020 | 5 | 226 | 430 | $169,088 | $53,992 |
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 41 | 88 | $27,808 | $7,717 | 27.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 15 | 45 | $28,070 | $7,340 | 26.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 77 | $13,760 | $4,663 | 33.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $10,000 | $2,656 | 26.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $7,036 | $2,191 | 31.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 21 | $5,389 | $1,914 | 35.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 12 | $2,676 | $826.20 | 30.9% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 22 | 29 | $2,465 | $701.86 | 28.5% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 34 | 87 | $59,334 | $14,504 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 38 | 74 | $23,148 | $6,949 | 30.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 46 | 76 | $19,456 | $5,868 | 30.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 55 | $9,790 | $2,985 | 30.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 18 | $9,000 | $2,725 | 30.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 49 | 156 | $96,174 | $26,543 | 27.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 58 | 115 | $29,483 | $9,069 | 30.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 26 | 41 | $12,556 | $3,846 | 30.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 23 | 23 | $11,452 | $3,510 | 30.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 12 | 13 | $2,817 | $823.19 | 29.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 64 | 173 | $95,323 | $30,706 | 32.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 74 | 144 | $37,008 | $11,945 | 32.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 43 | 44 | $22,000 | $6,952 | 31.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 26 | 41 | $7,380 | $2,372 | 32.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 19 | 28 | $7,377 | $2,017 | 27.3% |
About Dr. Dan Schuller, M.D
Dr. Dan Schuller, M.D is a Pulmonary Disease healthcare provider based in El Paso, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1467566042.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dan Schuller, M.D has received a total of $152,638 in payments from pharmaceutical and medical device companies, with $88.60 received in 2024. These payments were reported across 267 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($135,420).
As a Medicare-enrolled provider, Schuller has provided services to 721 Medicare beneficiaries, totaling 1,398 services with total Medicare billing of $158,822. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location El Paso, TX
- Active Since 08/19/2006
- Last Updated 10/21/2024
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1467566042
Products in Payments
- ELIQUIS (Drug) $62,944
- Letairis (Drug) $17,899
- XARELTO (Drug) $15,213
- Adempas (Drug) $6,313
- UTIBRON (Drug) $2,741
- OFEV (Drug) $193.65
- ZERBAXA (Drug) $152.91
- Esbriet (Biological) $142.89
- GIAPREZA (Drug) $103.44
- OPSUMIT (Drug) $99.99
- ORENITRAM (Drug) $78.00
- Doptelet (Drug) $77.50
- DOPTELET (Drug) $60.66
- OFIRMEV (Drug) $58.49
- REMODULIN (Drug) $36.64
- STIOLTO (Drug) $29.53
- TYVASO (Drug) $28.62
- AVYCAZ (Drug) $24.91
- CHANTIX (Drug) $23.92
- Kcentra (Biological) $23.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in El Paso
Dr. Hector Payan, M.d, M.D
Pulmonary Disease — Payments: $259,678
Dr. Juan Fernandez, Md, MD
Pulmonary Disease — Payments: $16,126
Adolfo Anchondo, M.d, M.D
Pulmonary Disease — Payments: $11,764
Dr. Carlo Hatem, Md, MD
Pulmonary Disease — Payments: $11,716
Dr. Jaime Quesada, Md, MD
Pulmonary Disease — Payments: $8,913
Dr. Fnu Bharat Ved Prakash, Md, MD
Pulmonary Disease — Payments: $5,355